ArticleFrontiers in oncology2024

Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11.

Vid Mlakar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.